Three Bridge Wealth Advisors LLC Buys New Position in Immunome, Inc. (NASDAQ:IMNM)

Three Bridge Wealth Advisors LLC purchased a new stake in Immunome, Inc. (NASDAQ:IMNM) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 27,615 shares of the company’s stock, valued at approximately $293,000.

Other large investors also recently made changes to their positions in the company. Janus Henderson Group PLC raised its holdings in shares of Immunome by 10.3% in the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after purchasing an additional 324,614 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Immunome by 217.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock valued at $6,469,000 after buying an additional 302,916 shares in the last quarter. Victory Capital Management Inc. increased its holdings in shares of Immunome by 48.1% in the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock valued at $10,684,000 after buying an additional 237,497 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Immunome by 13.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock valued at $17,657,000 after acquiring an additional 144,557 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in shares of Immunome by 22.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock worth $6,881,000 after acquiring an additional 85,580 shares in the last quarter. Institutional investors own 44.58% of the company’s stock.

Immunome Trading Up 1.3 %

Shares of IMNM stock opened at $10.40 on Thursday. Immunome, Inc. has a 1-year low of $8.97 and a 1-year high of $30.96. The stock’s fifty day simple moving average is $11.02 and its 200-day simple moving average is $12.51.

Insiders Place Their Bets

In related news, insider Robert Lechleider bought 15,805 shares of the business’s stock in a transaction on Thursday, November 21st. The stock was bought at an average price of $9.48 per share, for a total transaction of $149,831.40. Following the transaction, the insider now directly owns 15,805 shares in the company, valued at $149,831.40. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Clay B. Siegall bought 66,057 shares of the firm’s stock in a transaction on Thursday, November 21st. The shares were bought at an average cost of $9.54 per share, with a total value of $630,183.78. Following the purchase, the chief executive officer now directly owns 485,693 shares in the company, valued at approximately $4,633,511.22. This trade represents a 15.74 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 252,862 shares of company stock worth $2,140,545. 8.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on IMNM. Wedbush reaffirmed an “outperform” rating and set a $33.00 target price on shares of Immunome in a research report on Monday, January 13th. Piper Sandler cut their price objective on Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Finally, Stephens assumed coverage on shares of Immunome in a research note on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $28.60.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.